You are here

  • Home
  • Archive
  • Volume 19, Issue 9
  • Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor α

Article info

Article menu
Download PDFPDF
Cervical Cancer
Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor α

Authors

  1. Address correspondence and reprint requests to Alfonso Dueñas-Gonzalez, Av San Fernando 22, Col Sección XVI, Tlalpan, 14080 Mexico City, Mexico. E-mail: alfonso_duenasg{at}yahoo.com.

Citation

Candelaria M, Arias-Bonfill D, Chávez-Blanco A, et al
Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor α
International Journal of Gynecologic Cancer 2009;19:1632-1637.

Publication history

  • First published November 1, 2009.
Online issue publication 
March 06, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2009 by IGCS and ESGO